Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNIC ACID versus FUROSCIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNIC ACID versus FUROSCIX.
ETHACRYNIC ACID vs FUROSCIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Category C
Category C
Loop Diuretic
Loop Diuretic